Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ir J Med Sci ; 193(2): 755-760, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-37580623

RESUMO

ABSTACT: BACKGROUND: Coronavirus disease (COVID-19) currently named SARS-CoV-2 is a contagious disease caused by a coronavirus; incompatible data are present on the possible relationship among COVID-19 vaccines and hair loss. AIMS: The objective of the current study was to assess dermoscopically the prevalence of hair loss among an Egyptian population following COVID-19 vaccination. METHODS: A total of 2000 participants were enrolled in this cross-sectional study. Adult males and females who received one of recognized COVID-19 vaccine were included, irrespective of the status of previous COVID-19 infection. Those who were aged less than 18 years or above 60 years were excluded. Furthermore, subjects self-reporting hair loss were assessed by dermoscopy. RESULTS: Among the studied cases, n = 478 (23.9%) complained of hair loss following vaccination. The majority of cases noticed their hair loss during the first 2 months post-vaccination (n = 215 after the first month and n = 158 after the 2nd month respectively). CONCLUSION: We reported prevalence of post-vaccination hair fall that was confirmed by trichoscopy and which affected approximately one quarter of participants who received COVID-19 vaccines. Other factors, such as stress and infection, cannot be excluded and remain to be further investigated by larger multicenter studies.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Adulto , Masculino , Feminino , Humanos , Vacinas contra COVID-19/efeitos adversos , Estudos Transversais , Dermoscopia , Egito/epidemiologia , Prevalência , SARS-CoV-2 , COVID-19/epidemiologia , COVID-19/prevenção & controle , Alopecia/epidemiologia , Alopecia/etiologia , Vacinação/efeitos adversos
2.
J Cosmet Dermatol ; 21(11): 5790-5799, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-36039391

RESUMO

BACKGROUND: Androgenetic alopecia (AGA) is a common chronic dermatological illness that affects both men and women. AIM: To assess and compare dermoscopically the impact of a combination of topical minoxidil solution (5%) and topical spironolactone solution (5%) in treating AGA in both sexes. PATIENTS AND METHODS: One hundred and twenty patients diagnosed with AGA were divided into three groups; each group is composed of 40 patients. Group A (n = 40) were treated with a 5% topical minoxidil solution, group B (n = 40) were treated with a 5% topical spironolactone solution, and group C (n = 40) were treated with a 5% topical minoxidil and spironolactone combination. RESULTS: Following the initiation of treatment and at 6 weeks (midterm), reduction in all dermoscopic features was observed in all groups; however, it was not statistically significant except for vellus hair reduction (p = 0.033). On the contrary, upright regrowing hairs were insignificantly increased in all groups (p = 1.088). The pattern of dermoscopic features remained to insignificantly decrease toward the end of 12 weeks treatment (full term) in all studied groups except for vellus hair that showed further significant reduction toward the end of the study (p = 0.011). CONCLUSION: Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders. Furthermore, combining them in a single topical dose form can boost efficacy and yield greater advantages.


Assuntos
Minoxidil , Espironolactona , Feminino , Humanos , Masculino , Minoxidil/efeitos adversos , Espironolactona/efeitos adversos , Estudos Transversais , Resultado do Tratamento , Método Duplo-Cego , Alopecia/diagnóstico por imagem , Alopecia/tratamento farmacológico , Administração Tópica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...